Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer – FDA approval marks Alpha Tau's fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT's reach into recurrent prostate cancer – GlobeNewswire December 02, 2025 JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (NASDAQ: […]